Search results
Showing 91 to 105 of 249 results for carcinoma
Telbivudine for the treatment of chronic hepatitis B (TA154)
Evidence-based recommendations on telbivudine (Sebivo) for treating chronic hepatitis B in adults.
Awaiting development [GID-TA11019] Expected publication date: TBC
Endoscopic submucosal dissection of oesophageal dysplasia and neoplasia (IPG355)
Evidence-based recommendations on endoscopic submucosal dissection (ESD) of oesophageal dysplasia and neoplasia. This involves inserting a long camera through the mouth into the oesophagus to view the area and removing the abnormal part with special instruments.
View recommendations for IPG355Show all sections
Sections for IPG355
This guideline covers how to communicate the risks and benefits of natural sunlight exposure (specifically, the ultraviolet rays UVA and UVB) to help people understand why they may need to modify their behaviour to reduce their risk of skin cancer and vitamin D deficiency.
Awaiting development [GID-TA10911] Expected publication date: TBC
Transurethral laser ablation for recurrent non-muscle-invasive bladder cancer (IPG656)
Evidence-based recommendations on transurethral laser ablation for recurrent non-muscle-invasive bladder cancer in adults. This involves using a laser inserted into the bladder to destroy the cancer cells.
View recommendations for IPG656Show all sections
Endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus (IPG497)
Evidence-based recommendations on endoscopic radiofrequency ablation for squamous dysplasia of the oesophagus. This involves using radiofrequency (heat) energy to destroy the abnormal cells and to promote the growth of healthy squamous cells.
Evidence-based recommendations on pembrolizumab (Keytruda) with lenvatinib (Lenvima) for treating advanced or recurrent endometrial cancer in adults.
Belzutifan for treating tumours associated with von Hippel-Lindau disease [ID3932]
In development [GID-TA10817] Expected publication date: TBC
This guideline covers assessing and managing suspected or confirmed cirrhosis in people who are 16 years or older. It aims to improve how cirrhosis is identified and diagnosed, and gives advice on the monitoring, prevention and early management of complications.
Nivolumab for adjuvant treatment of invasive urothelial cancer at high risk of recurrence (TA817)
Evidence-based recommendations on nivolumab (Opdivo) for adjuvant treatment of invasive urothelial cancer at high risk of recurrence.
Intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer (IPG628)
Evidence-based recommendations on intravesical microwave hyperthermia and chemotherapy for non-muscle-invasive bladder cancer in adults. This involves using microwaves to improve the effect of the chemotherapy given directly into the bladder.
View recommendations for IPG628Show all sections
This guideline covers care for people with a family history of breast, ovarian or another related (prostate or pancreatic) cancer. It aims to improve the long-term health of these families by describing strategies to reduce the risk of and promote early detection of breast cancer (including genetic testing and mammography). It also includes advice on treatments (tamoxifen, raloxifene) and surgery (mastectomy).
Laparoscopic nephrectomy (including nephroureterectomy) (IPG136)
Evidence-based recommendations on laparoscopic nephrectomy (including nephroureterectomy). This involves making small incisions (keyhole surgery) to remove the damaged kidney, or kidney, ureter and surrounding tissue.
View recommendations for IPG136Show all sections
Sections for IPG136
Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659
Awaiting development [GID-TA11111] Expected publication date: TBC